Page 2,489«..1020..2,4882,4892,4902,491..2,5002,510..»

cord blood banking | Advancing Cord Blood Stem Cell Research Tackles Wide Range of Serious Diseases – Video

Posted: December 13, 2012 at 12:44 pm


cord blood banking | Advancing Cord Blood Stem Cell Research Tackles Wide Range of Serious Diseases
http://www.cordbloodrecommendation.com The real treatment takes place when the patient is infused with stem cells, which start producing white blood cells in order to make the amount of white blood cells reach the normal number. The treatment that has to be provided for leukemia should be such, that it would increase the amount of White Blood cells in the blood stream. This is part of the reason for the high cost. The banking facility helps in making blood donation readily available for transplantation #39;s. This is time consuming, and chances of perfect matches are not very high either. Ask tough questions. In addition, for the yearly maintenance fees will be about hundreds of dollars. We were lucky that when our son was born my parents wanted to give it to us as a gift. How to do cord blood banking?All you need to do is store your newborn baby #39;s umbilical cord and placenta during delivery with some medical aid. An unfussy decision in pregnancy can present a game trace of stem groups with no doubts about incompatibility. Your child #39;s umbilical cord blood contains special cells known as stem cells. Not all material is fit for donation. This is currently what the cord blood banking cost is in the year 2010. It was observed that the hematopoietic recovery and endurance of the receivers of unmanipulated umbilical cord blood were similar to those who received volume reduced umbilical blood from cord. Blayke and Garrett #39;s immune systems were unable to successfully fight off germs ...From:loshoteles enmedellinViews:0 0ratingsTime:01:18More inScience Technology

Read the rest here:
cord blood banking | Advancing Cord Blood Stem Cell Research Tackles Wide Range of Serious Diseases - Video

Posted in Stem Cell Research | Comments Off on cord blood banking | Advancing Cord Blood Stem Cell Research Tackles Wide Range of Serious Diseases – Video

SU2C-CRI Cancer Immunology Translational Research Dream Team – Video

Posted: December 13, 2012 at 12:44 pm


SU2C-CRI Cancer Immunology Translational Research Dream Team
Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology mdash; "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy." Cancer immunology is a field of research that explores the complex relationship between cancer and the immune system, with the goal of discovering immune-based solutions to curing cancer. The SU2C-CRI Cancer Immunology Translational Research Dream Team will receive $10 million in funding over three years for this translational cancer research project that will unite laboratory and clinical efforts leading to the immunological treatment, control and prevention of cancer. The team will be led by James P. Allison, Ph.D., and Antoni Ribas, MD, Ph.D. Allison is chairman of the department of immunology, director of the immunotherapy platform and co-director of the David H. Koch Center for Applied Research of Genitourinary Cancers at The University of Texas MD Anderson Cancer Center. Ribas is professor of medicine, surgery and molecular and medical pharmacology, director of the tumor immunology program area at the Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles (UCLA). "The goal of our Dream Team is to expand, optimize and explore combinations of two novel immunotherapies, immune checkpoint blockade and adoptive T-cell transfer ...From:CancerResearchInstViews:14 1ratingsTime:03:37More inNonprofits Activism

Read the original:
SU2C-CRI Cancer Immunology Translational Research Dream Team - Video

Posted in Stem Cell Research | Comments Off on SU2C-CRI Cancer Immunology Translational Research Dream Team – Video

BioLife Solutions Announces TiGenix’s Completion of Stem Cells and HypoThermosol® Clinical Trial

Posted: December 13, 2012 at 7:51 am

BOTHELL, Wash., Dec. 12, 2012 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today announced that its customer TiGenix NV (Euronext Brussels: TIG) has completed a phase I clinical safety trial of its expanded adipose-derived stem cell platform incorporating BioLife's cGMP HypoThermosol cell/tissue storage/shipping medium.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

The clinical trial, titled "Phase I Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs)," assessed the safety, tolerability and feasibility of a potential cell-based therapy TiGenix is developing for a number of autoimmune disorders including rheumatoid arthritis.

Eduardo Bravo, TiGenix CEO, remarked on the selection of HypoThermosol as a combination shipping medium and vehicle solution for TiGenix's stem cell technology, "HypoThermosol allows us to increase the stability profile of our clinical cell-based products and considerably extends their shelf-life. Increased shelf-life of cell therapy products will be key in future commercial distribution."

Mike Rice, BioLife Solutions Chief Executive Officer, said, "We want to congratulate TiGenix on this important milestone. They join a growing list of regenerative medicine companies that have adopted our best in class biopreservation media products in the development of their clinical cell and tissue based therapies. We're very pleased to support their clinical product development."

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company's proprietary HypoThermosol and CryoStor platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit http://www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Continued here:
BioLife Solutions Announces TiGenix's Completion of Stem Cells and HypoThermosol® Clinical Trial

Posted in Stem Cells | Comments Off on BioLife Solutions Announces TiGenix’s Completion of Stem Cells and HypoThermosol® Clinical Trial

Research and Markets: Global Stem Cells Pipeline Capsule – 2012

Posted: December 13, 2012 at 7:51 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/557jct/global_stem_cells) has announced the addition of the "Global Stem Cells Pipeline Capsule - 2012" report to their offering.

Fore Pharma's latest report 'Global Stem Cells Pipeline Capsule - 2012' provides up-to-date information on key Research and Development activities (R&D) in the global stem cells market. It covers active stem cells pipeline molecules in various stages of clinical trials, preclinical research, and drug discovery.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating opportunities, formulating business development strategies, executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the R&D stages. It also provides information on pipeline molecules developed in leading geographies (North America and Europe). Licensing activities are thoroughly captured in this report.

Key Features of the Report:

- Stem Cells: Overview

- Stem Cells Pipeline Overview

- Stem Cells Phase 3 Clinical Trial Pipeline Insights

- Stem Cells Phase 2 Clinical Trial Pipeline Insights

See original here:
Research and Markets: Global Stem Cells Pipeline Capsule - 2012

Posted in Stem Cells | Comments Off on Research and Markets: Global Stem Cells Pipeline Capsule – 2012

Avascular necrosis stem cell therapy in mumbai – Video

Posted: December 13, 2012 at 7:48 am


Avascular necrosis stem cell therapy in mumbai
This video explores the patient #39;s condition before and after treatment.It is published by StemRx India. Avascular necrosis stem cell therapy in mumbai for more information visit http://www.stemrx.inFrom:StemRx BioScienceViews:3 0ratingsTime:04:07More inScience Technology

Read the original here:
Avascular necrosis stem cell therapy in mumbai - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Avascular necrosis stem cell therapy in mumbai – Video

Randall avoids knee replacement surgery after adult stem cell therapy by Dr Harry Adelson – Video

Posted: December 13, 2012 at 7:48 am


Randall avoids knee replacement surgery after adult stem cell therapy by Dr Harry Adelson
Randall describes his experience with adult stem cell therapy by Dr Harry Adelson on his arthritic knee and ankleFrom:Harry AdelsonViews:0 0ratingsTime:01:08More inScience Technology

View post:
Randall avoids knee replacement surgery after adult stem cell therapy by Dr Harry Adelson - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Randall avoids knee replacement surgery after adult stem cell therapy by Dr Harry Adelson – Video

BrainStorm Receives 3 Million NIS Grant from Israel’s Office of the Chief Scientist

Posted: December 13, 2012 at 7:48 am

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded a 3 million NIS grant from Israels Office of the Chief Scientist (OCS) for the year 2013. The grant is intended to support BrainStorms Research and Development program for its innovative stem cell therapy candidate NurOwn.

We are thankful to the OCS for its continued support of our Research and Development program. The non-dilutive capital funding from the OCS will help facilitate continuation of our clinical trials in Israel, as well as our preparations for clinical trials in the USA, said Dr. Adrian Harel, BrainStorms CEO.

The OCS has supported BrainStorm Cell Therapeutics Ltd. since 2007, providing grants of a total of $1.8 million until today. The Company is required to pay royalties to the OCS, amounting to 3% - 3.5% of revenues derived from sales of the products funded with these grants, but only up to the amount equal to 100% of the grants received plus LIBOR interest.

As reported by Brainstorm on Monday December 10, the Company anticipates announcing a new date for its shareholders teleconference shortly.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

About the Office of the Chief Scientist

The Office of the Chief Scientist (OCS) in Israels Ministry of Industry, Trade and Labor is charged with execution of government policy for support of industrial R&D. The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel's scientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally.

Safe Harbor Statement

View original post here:
BrainStorm Receives 3 Million NIS Grant from Israel’s Office of the Chief Scientist

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on BrainStorm Receives 3 Million NIS Grant from Israel’s Office of the Chief Scientist

Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive …

Posted: December 13, 2012 at 12:45 am

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today summarized ADCETRIS (brentuximab vedotin) data in relapsed Hodgkin lymphoma (HL) and other CD30-positive malignancies from multiple presentations at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Highlights include compelling survival data from long-term follow up in a pivotal clinical trial of ADCETRIS in relapsed or refractory HL and a retrospective comparison of overall survival among patients treated with ADCETRIS to those not treated with ADCETRIS following an autologous stem cell transplant (ASCT). In addition, data describe the activity and tolerability of ADCETRIS in the salvage HL setting from an investigator-sponsored trial and in relapsed patients age 60 or over with CD30-positive malignancies, including HL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL.

"There are more than a dozen data presentations at ASH evaluating the use of ADCETRIS in CD30-positive malignancies and we are very encouraged by both the broad application across multiple hematologic disease areas as well as the encouraging activity associated with ADCETRIS, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. The extensive investigator and corporate data presentations at ASH clearly demonstrate the important role ADCETRIS plays in the treatment of relapsed HL and systemic anaplastic large cell lymphoma and the promise of the role it potentially will play in additional future indications.

Long-term Survival Analysis of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma (Abstract #3689)

A pivotal, single-arm trial was conducted in 102 relapsed or refractory HL patients after ASCT to assess efficacy and safety of single-agent ADCETRIS. In addition, the trial was designed to determine duration of response, progression-free survival and overall survival. Enrolled patients had received a median of more than three prior chemotherapy regimens.

Data highlights from the long-term survival analysis in the pivotal trial were:

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant (Abstract #3701)

An independent retrospective comparison conducted by MD Anderson Cancer Center evaluated overall survival in 102 relapsed HL patients treated with ADCETRIS in a pivotal clinical trial compared to data from 756 relapsed HL patients treated at six international centers (Horning et al., 2008). The authors compared median overall survival, starting at the time of receiving an ASCT, among ADCETRIS treated patients to patients not treated with ADCETRIS. Key findings, which were highlighted in a presentation by Dr. Meghan Karuturi from MD Anderson Cancer Center, included:

Brentuximab Vedotin as a First Line Salvage Therapy in Relapsed/Refractory HL (Abstract #3699)

An investigator-sponsored trial was conducted to evaluate ADCETRIS as a salvage therapy for HL. Fourteen patients were evaluated for response and safety and all had relapsed or refractory HL after initial therapy with the chemotherapy regimens ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine hydrochloride, prednisone) or a combination of chemotherapy with or without consolidative radiation treatment. Patients were treated with ADCETRIS every three weeks for a maximum of four cycles. Data were presented by Dr. Robert Chen from City of Hope National Medical Center in Duarte, CA.

Original post:
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive ...

Posted in Genetics | Comments Off on Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive …

A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments

Posted: December 13, 2012 at 12:44 am

Tweet 


Further to my recent post, "Six steps to fighting non-compliant cell therapy treatments. The stuff of grey shades, spades, ivory towers and (ahem) balls.", I have crafted a 6-point platform that I propose to submit (with potential edits based on preliminary feedback) to several of the leading  industry and professional organizations for their consideration including ARM, ISCT, ISSCR, FACT, AABB  ICMS, and perhaps, in due course, to patient groups, physician groups, disease-specific professional organizations (e.g, cardiology, oncology, neurology, cosmetic, etc).



I welcome comments and feedback. 


1. In addition to helping patients distinguish between compliant and non-compliant treatments (and providers) we must do more to help patients distinguish between non-compliant cell therapy treatments (and providers) which are more or less risky. 


2. Whatever we do in response to this issue should be done with an eye to being practical and helpful to patients in the real-life context of their decision about whether or not to buy a non-complaint cell therapy.


3. Our response to this issue should be based on a risk-based approach recognizing that not all non-compliance is created equal.  We should create a framework for risk-based analysis (both for us and our audiences) and focus initiatives around those which present the highest risk.


4. We recognize the problem of non-compliant cell therapies is not just a problem that exists in jurisdictions with little, no, or poor regulation but that is a growing problem even in the most highly regulated jurisdictions meaning the solution cannot be regulated it depends on education and enforcement.


5. We recognize regulatory agencies cannot enforce non-compliance on their own.  We as an industry need to complement their efforts through our own standards and enforcement.


6. Stakeholder groups should support the formation of a multi-organizational  initiative to, based on a risk-based assessment, spotlight the categories or signs of highest-risk offenders for use by patients and/or their physicians in identifying  whether or not treatments (and providers) they may be considering fall into the that category associated with the highest level of risk.


What do you think?

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/wkSMxAV9938/a-proposed-6-step-platform-for-cell.html

Posted in Regenerative Medicine | Comments Off on A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments

LA Times: On the California Stem Cell Agency and Wasting $700,000

Posted: December 13, 2012 at 12:04 am

The headline on the Los Angeles
Times web site this afternoon read,

"Is California's stem cell program
preparing to waste $700,000?"

The question was raised by Pulitzer
Prize-winning columnist Michael Hiltzik, whowas commenting on the presentation today by the
prestigious Institute of Medicine's (IOM) on its sweeping
recommendations for changes at the state stem cell agency. 
Hiltzik wrote, 

"If you're betting that
the California
stem cell agency will spurn key recommendations of a
blue-ribbon review panel that criticized its leadership and
management structures, you might want to double that bet. Several
board members showed overt hostility to the panel's recommendations
during a public meeting today."

Harold Shapiro, chairman of the IOM
panel and former president of Princeton University, delivered
the briefing. The group's study took 17 months and cost the stem cell
agency $700,000.
Hiltzik's piece summarized the IOM
proposals, which echoed many criticisms that have been aired for
years in California.  Hiltzik wrote, 

"CIRM Chairman Jonathan
Thomas glided over those issues when he introduced Shapiro.
Thomas observed that the Institute of Medicine report included many
statements "validating CIRM, its process, what it was able to
achieve," which is a bit like launching the investigation of a
plane crash by focusing on all the planes that land safely every day.
Thomas did mention that the Institute of Medicine had made numerous
recommendation about how to "take something which is already a
great experience and improve it even further." 

"Shapiro got only a few minutes
into his presentation before board members started interrupting him
with objections to the Institute of Medicine's recommendation for a
majority of independent members."

Hiltzik concluded, 

"Thomas promised to stage a public
workshop on the Institute of Medicine report soon and to subject them
to 'lengthy discussion.' 

"Does that sound as if the board
will be taking seriously the advice that it change the way it does
business? Stay tuned, but don't hold your breath."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/9CY8_m5Reqo/la-times-on-california-stem-cell-agency.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on LA Times: On the California Stem Cell Agency and Wasting $700,000

Page 2,489«..1020..2,4882,4892,4902,491..2,5002,510..»